ZAY Stock Overview Engages in the research and development of graphene and related nanomaterials in Canada. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Zentek Historical stock prices Current Share Price CA$1.06 52 Week High CA$1.08 52 Week Low CA$0.57 Beta 1.17 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change -54.70% 5 Year Change 338.02% Change since IPO 192.01%
Recent News & Updates
Zentek Ltd. Provides Update on ZenGUARD Enhanced Air Filters for the Canadian Market Jan 17
High number of new and inexperienced directors Jan 06
Zentek Ltd. Announces its Decision That its ZenGUARD Enhanced Air Filters Will Be Added Under the Existing Medical Device Establishment Licence Nov 27
High number of new and inexperienced directors Nov 26
Zentek Ltd. Provides Regulatory Update for ZenGUARD(TM) Enhanced Air Filters Nov 02
Zentek Ltd. Provides Market Update on ZenGUARD Antimicrobial Surgical Masks Oct 17 See more updates
Zentek Ltd. Provides Update on ZenGUARD Enhanced Air Filters for the Canadian Market Jan 17
High number of new and inexperienced directors Jan 06
Zentek Ltd. Announces its Decision That its ZenGUARD Enhanced Air Filters Will Be Added Under the Existing Medical Device Establishment Licence Nov 27
High number of new and inexperienced directors Nov 26
Zentek Ltd. Provides Regulatory Update for ZenGUARD(TM) Enhanced Air Filters Nov 02
Zentek Ltd. Provides Market Update on ZenGUARD Antimicrobial Surgical Masks Oct 17
High number of new and inexperienced directors Oct 02 Zentek Ltd. announced that it has received CAD 3.06995 million in funding Aug 20
Zentek Ltd. announced that it expects to receive CAD 3 million in funding
Zentek Ltd. Announces Board and Management Changes May 06
Zentek Ltd. Provides ZenGUARD Business Update Apr 27 Zentek Ltd.'s Subsidiary Triera Biosciences Ltd. Completes Testing of Its C19HBA Aptamer as Potential Therapeutic Jan 31
Zentek Ltd. Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters Jan 22
Zentek Ltd. Announces Board Changes Jan 19
Zentek Ltd. Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant Nov 30
High number of new and inexperienced directors Nov 24
Zentek Ltd. announced a financing transaction Nov 23 Zentek Ltd. announced a financing transaction Nov 22
Zentek Ltd. Completes Return on Investment Analysis for Canadian Healthcare System Oct 18 Zentek Ltd. Elects John Snisarenko as Director
High number of new and inexperienced directors Sep 21
Zentek Ltd Announces the Successful Results of A Recent Study Conducted by ParticleOne Sep 12
Zentek Ltd. Announces the Results of Study Comparing the Viral Filtration Efficiency of Its Zenguard-Enhanced MERV 9 Filters with an Uncoated MERV 9 Filter Sep 07 Zentek Ltd., Annual General Meeting, Oct 05, 2023 Aug 01
Zentek and McMaster Announce Positive Results for Aptamer-Based Technology with Therapeutic Potential Jul 22
Zentek Ltd. Announces Updates to Senior Management Team Jul 14
Zentek Receives a Deficiency Letter from Nasdaq Stock Market LLC Jul 01
Zentek Ltd. Appoints Lisa Sim to the Board of Directors Jun 02
Albany Graphite Corp. acquired Albany Graphite Project from Zentek Ltd. for approximately CAD 136 million. May 25
Zentek Ltd. Introduces A Novel Corrosion Protection Technology: ZenARMOR Feb 09
Zentek Ltd. Receives the Final Report for Phase 2 Testing of Zenguardtm for Use in Heating Feb 08
Zentek Ltd. Receives the Final Report for Phase 2 Testing of Zenguardtm for Use in Heating Feb 07
Zentek Ltd. Announces Appointment of Mitch Swergold as Director of Investor Relations Jan 13
Zentek Ltd Announces Successful Phase 2 Results of HVAC Testing Dec 17
Less than half of directors are independent Nov 21
Zentek Ltd. Provides Update on Battery Technology Development Oct 29
Zentek Provides Update on Icephobic Coating Technology Sep 20
Zentek Ltd. Provides Update on HVAC Testing Sep 16
Less than half of directors are independent Sep 13
Zentek Ltd., Annual General Meeting, Sep 29, 2022 Jul 30
Less than half of directors are independent Jul 28
Zentek Files Provisional Patent on the Use of ZenGUARD as an Anti-Inflammatory Agent Jul 19
Zentek Ltd. Appoints Ilse Treurnicht to Its Board of Directors Jul 06
Zentek Ltd. Provides Update on ZenGUARDTM Patent Status Jun 07 Zentek Ltd. Announces Chief Financial Officer Changes
Less than half of directors are independent May 12
Zentek Ltd. Announces Start of Phase Two Testing of Zenguardtm -Coated Filters Apr 12
Zentek Ltd. Announces Filing of Provisional Patent for Fire-Retardant Additive Mar 29
Less than half of directors are independent Mar 24 Zentek Ltd. Appoints Ravi Kaza to Its Advisory Board Mar 10
Zentek Ltd. Announces Development of Graphene-Wrapped Silicon Anodes Feb 19
Less than half of directors are independent Feb 07
Zentek Ltd. announced that it has received CAD 10.009022 million in funding Jan 06
Zentek Ltd. announced that it expects to receive CAD 10.009022 million in funding Dec 24
Less than half of directors are independent Dec 02
Less than half of directors are independent Nov 10
CEO & Director recently bought €102k worth of stock Oct 06
Zen Graphene Solutions and Trebor Rx Announce Health Canada Approval for ZENGuardTM Mask Sep 24
CEO & Director recently bought €98k worth of stock Aug 01
ZEN Graphene Solutions Ltd. Develops Stable Diesel Fuel Additive Jun 02
ZEN Graphene Solutions Ltd. announced that it has received CAD 4.337998 million in funding Apr 10
ZEN Graphene Solutions Ltd. announced that it expects to receive CAD 2 million in funding Mar 26
ZEN Graphene Solutions Ltd. Announces Successful Testing of its Graphene Compound Against Antimicrobial-Resistant Bacteria Mar 18 ZEN Graphene Solutions and Trebor Rx Corp. Announce Successful Health Canada Testing Requirements of Surgical Masks
Zen Graphene Solutions Announces Initial Phase 2 Cytotoxicity Results for Its Graphene-Based Compound Feb 05
ZEN Graphene Solutions Ltd. Announces Management Changes Jan 22
New 90-day high: €2.34 Jan 10
Zen Graphene Solutions Ltd. Provides Update on Cytotoxicity Testing of Graphene-Based Compound and Effectiveness of Graphene-Based Coating Dec 30
New 90-day high: €1.25 Dec 24
Vice President of Operations recently sold €107k worth of stock Dec 19
ZEN Graphene Solutions Ltd. Appoints Gregory Fenton as New Chief Executive Officer Dec 10
New 90-day high: €0.83 Nov 05
Zen Graphene Solutions Ltd. Announces New Research Collaboration Agreement on Carbon Aerogels with Deutsches Zentrum fuer Luft- und Raumfahrt e. V Oct 16
New 90-day high: €0.55 Oct 13
ZEN Graphene Solutions Ltd. Solutions Signs 2 Year Extension with Chemisar Laboratories Inc Oct 11
Zen Graphene Solutions and Guelph University Researchers File Patent on Graphene Oxide Production Method Oct 05 Shareholder Returns ZAY DE Medical Equipment DE Market 7D 0% -0.8% 0.3% 1Y n/a -4.9% 12.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how ZAY performed against the German Market .
Price Volatility Is ZAY's price volatile compared to industry and market? ZAY volatility ZAY Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: ZAY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine ZAY's volatility change over the past year.
About the Company Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis.
Show more Zentek Ltd. Fundamentals Summary How do Zentek's earnings and revenue compare to its market cap? ZAY fundamental statistics Market cap €112.00m Earnings (TTM ) -€7.23m Revenue (TTM ) €26.47k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ZAY income statement (TTM ) Revenue CA$39.36k Cost of Revenue CA$479.45k Gross Profit -CA$440.10k Other Expenses CA$10.30m Earnings -CA$10.74m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.10 Gross Margin -1,118.24% Net Profit Margin -27,291.69% Debt/Equity Ratio 2.8%
How did ZAY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/04 07:44 End of Day Share Price 2025/01/07 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Zentek Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Troy Jensen Lake Street Capital Markets, LLC Joseph Reagor Roth Capital Partners
